GLP-1 Drug Use in U.S. Households Rises to 21 Percent in 2026
The rapid growth of GLP-1 adoption across American households is creating measurable downstream effects on consumer behavior, home design, and medical waste disposal that federal agencies have not...
One in five U.S. Households, or 21 percent, now includes at least one current GLP-1 user as of November 2026, up from 9 percent in January 2025, according to survey data reported by the New York Post. That represents a 12-percentage-point increase in roughly ten months, a pace that researchers and housing industry observers say is producing visible changes in residential design and household waste patterns.
GLP-1 medications, a class of glucagon-like peptide-1 receptor agonists that includes semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound), are administered primarily through self-injection. The drugs received FDA approval for type 2 diabetes and, separately, for chronic weight management. The FDA approval records for semaglutide for weight management (Wegovy) are publicly available through the FDA's drug database under NDA 215256.
The growth in household adoption has practical consequences for home infrastructure. According to the New York Post report, custom bathroom vanities are increasingly being designed to include under-counter refrigerators for medication storage, dedicated drawer compartments for syringes, and built-in sharps disposal containers for used needles. These design modifications reflect clinical storage requirements: the FDA's prescribing information for semaglutide specifies that unopened pens must be refrigerated between 36 and 46 degrees Fahrenheit.
The sharps disposal question carries a regulatory dimension. The U.S. Environmental Protection Agency does not regulate household medical waste disposal at the federal level, leaving that authority to individual states. The EPA's guidance page on household sharps disposal, last updated in 2024, notes that at least 38 states have laws or regulations governing how residents may dispose of used needles, but those rules vary significantly and enforcement at the household level is limited.
The volume of used syringes entering the household waste stream is not tracked by any single federal database. The Centers for Disease Control and Prevention estimated in a 2022 report that approximately 7.8 billion needles and syringes are used annually in the United States across all therapeutic categories, though that figure predates the GLP-1 adoption surge and would not reflect current volumes. A revised estimate covering 2025 or 2026 is not currently available from the CDC or the EPA.
Federal spending on GLP-1 drugs through public programs is a subject of active legislative debate. Medicare Part D, administered by the Centers for Medicare and Medicaid Services, does not currently cover GLP-1 medications for weight loss under existing statutory authority, though it covers them for type 2 diabetes. The Treat and Reduce Obesity Act, which has been introduced in multiple Congresses and would expand Medicare coverage, was reintroduced in the 119th Congress. Its current status in committee can be verified through Congress.gov by searching bill number.
The Medicaid landscape is fragmented. A 2024 KFF analysis found that 13 states covered at least one GLP-1 drug for obesity through their Medicaid programs, while others restricted coverage to diabetes indications only. Because Medicaid is jointly funded by states and the federal government, USASpending.gov does not provide a consolidated line item for GLP-1 drug expenditures across all state programs.
The housing industry angle reported by the New York Post connects to a broader federal policy area. The Department of Housing and Urban Development does not currently publish accessibility or design guidelines specific to in-home medication storage or medical waste disposal, according to a review of HUD's publicly available design standards. Whether HUD or the Fair Housing Act's accessibility requirements would ever extend to such features is not addressed in current regulatory text.
The affordability dimension of GLP-1 adoption is separately documented. The list price for a monthly supply of Wegovy was approximately $1,350 as of 2024, according to the manufacturer's published list price, though actual out-of-pocket costs vary by insurance coverage and income-based assistance programs. That price point means household adoption at the current rate is concentrated among insured or higher-income populations, though the survey data cited by the New York Post does not break down the 21 percent figure by income quintile or insurance status.
What remains unknown is the precise federal cost exposure as GLP-1 adoption continues to rise, the actual volume of sharps waste entering municipal waste streams, and whether any federal agency plans to issue updated guidance on household medical waste disposal specific to self-injectable drugs. The document that would answer the federal cost question most directly would be CMS's annual Medicare and Medicaid drug spending dashboards, which are updated periodically and are publicly available at data.cms.gov.